Organigram Global Inc. · TSX:OGI
Organigram Global — Q3 2025 Earnings Presentation
25 slides from Organigram Global's earnings presentation, Aug 13, 2025
Slide 1: Investor Presentation
Investor Presentation March 31, 2025
Slide 2: Cautionary Statement
CAUTIONARY STATEMENT This document is current as of March 31, 2025, except where otherwise management’s discussion and analysis and other Company documents filed information regarding these non-IFRS measures, including definitions, and a stated. The information contained in this presentation is prov
Slide 3: Mission and Vision
MISSION A cannabis friendly future. VISION, To be a respected global leader, meetin the evolving needs of the consumer of tomorrow. INTEGRITY fmm | pm | ACCOUNTABILITY CURIOSITY TEAMWORK ORGANIGRAM
Slide 4: Canadian Roots. Naturally Global.
Canadian Roots. Naturally Global. 12 YEARS OF WORLD CLASS INNOVATION GLOBAL RAPID RESPONSIBLE CAPABILITIES TRAILBLAZER STRATEGIC INTERNATIONAL LEADERSHIP INVESTOR EXPANSION Founded in 2013, Organigram operates five Organigram is a leader Organigram has received over Organigram has achieved Organigra
Slide 5: Canada's #1 LP in market
PRE-ROLLS MILLED (including IPRs) HASH FLOWER Canada’s #1 #1 #1 #1 LP in market share1 VAPES FLOWER (including milled) GUMMIES RECREATIONAL MARKET #1 #3 #3 1. Multiple Sources (Hifyre, Weedcra wler, pr ovincial boar ds, internal modelling) as of Mar ch 31, 2025
Slide 6: Coast to Coast Leadership
Coast to Coast Leadership # 1 WESTERN CANADA # 1 EASTERN CANADA 1 # CENTRAL CANADA Moncton Facility Winnipeg Lac-Supérieur Facility Facility London & Aylmer Facilities (Motif) Multiple Sources (Hifyre, Weedcraw ler, provincial boards , internal modelling) as of March 31, 2025
Slide 7: Current Global Distribution
Current Global Distribution I NVESTOR SE SSI O N • 20 25
Slide 8: State-of-the-art Facilities
State-of-the-art Facilities Canada’s largest indoor cultivation Recently-acquired Motif operations are located across two facilities in Aylmer and London, Ontario Winnipeg, MB Aylmer, ON London, ON Lac-Supérieur, QC Moncton, NB Edibles facility with Advanced capabilities & Centralized distribution h
Slide 9: Portfolio of Beloved Brands
Portfolio PREMIUM of Beloved Brands MAINSTREAM Delivering strong coverage across all segments and categories FLOWER MILLED VALUE PRE-ROLLS INFUSED PRE-ROLLS VAPES BEVERAGES EDIBLES HASH CONCENTRATES OILS
Slide 10: Brand highlights and annual retail sales
• $224 million annual retail sales 1 • $150 million annual retail sales1 • Premium innovation brand • Award-winning mainstream brand with • #1 Canadian vape brand 1 • First Organigram brand to launch broad category coverage • Portfolio includes IPRs, and other 2.0 proprietary FASTTM products which •
Slide 11: Motif Acquisition Cost Synergies on Track
Acquisition Cost Synergies on Track — Completed December 2024 and Exceeding Expectations Consolidation of logistics and warehousing through the acquisition of the London facility – a central Canada hub for key markets Revenue Expansion Drives Margin Improvement Shared procurement and supplier re
Slide 12: Collective Project Acquisition
Collective Project Acquisition Completed March 2025 Deal Rationale Fast tracks Organigram’s entry into the beverages category Leverages the strength of the Collective Arts brand in the U.S. Organigram will be able to leverage the relationships and infrastructure that Collective Arts has built
Slide 13: Strategic Investments from BAT
Strategic Investments from BAT: 2024 Over $345 Million Invested $125 Million 2021 • Creation of strategic investment pool named Jupiter, funded with $83.1 million $221 Million • $41.5 million proceeds for general corporate purposes • Final $41.5 million tranche closed in February 2025 • Establish
Slide 14: Investment Pool
Priority Investment Pillars Investment Pool Geographies • • U.S. Emerging global markets The $83.1 million Jupiter investment Categories & Tech pool targets investments in emerging • • Non-combustible inhalation Edibles • Beverages cannabis opportunities • All potential investments are made in align
Slide 15: Investment in Germany and Europe
Investment in Germany and Europe GERMANY AND EUROPE • $21 million investment into German cannabis leader Sanity Group to establish foothold in rapidly growing German market and expand export volume to Europe. • Expansion of Organigram’s previously announced supply agreement with Sanity Group • Oppor
Slide 16: Investment in Seed Technology
Investment in Seed Technology SEED-BASED TECHNOLOGY • Up to U.S.$8 million investment (U.S.$7 million invested to-date) into U.S.-based Phylos Bioscience to access flower- derived minor cannabinoids such as THCV and initiate the conversion of a portion of Organigram’s garden to more cost-effective s
Slide 17: Seed vs. Clone Cultivation
Seed vs. Clone Cultivation One-week-old Three-weeks-old CLONE SEEDLING CLONE SEEDLING
Slide 18: Seeds: More Robust and Uniform
Seeds: More Robust and Uniform Uniformity and Robustness of Seed Grow Clones Seeds
Slide 19: Non-Combustible Formats, Manufacturing & Formulation
NON-COMBUSTIBLE FORMATS MANUFACTURING & FORMULATION • $5.5 million investment into Green Tank Technologies • U.S.$2 million investment into Corp., a vape R&D firm and hardware manufacturer U.S.-based OBX • New hardware provides more consistent flavour, • A leading hemp-derived cannabinoid reduces cl
Slide 20: Increasing International Sales
Increasing International Sales $6.1 • Strong international $4.1 sales trajectory $3.3 • EU-GMP expected to boost $2.4 $2.2 sales and margins • Diversified client list $1.0 • Introduction of sales from Collective Project Limited ("Collective Project") Q1 F24 Q2 F24 Q3 F24 Q4 F24 Q1 F25 Q2 F25 (millio
Slide 21: Q2 F'2025 Highlights
Revenue and Margins (millions) Q2 F'2025 Highlights 36% 37% • Record Gross Revenue of $102.8 million (+79% 33% 33% 31% 31% year-over-year) 102.8 • Record Net Revenue of $65.6 million (+74% year- 20% over-year) 19% $69.9 $66.8 • Adjusted EBITDA1 of $4.9 million $63.6 $56.2 $56.3 $57.4 • Net Income of
Slide 22: Balance Sheet Strength
Balance Sheet Strength AS OF END OF Q2 Fiscal 2025: 83.4 million $58 million Total cash reserved for the (including restricted cash Jupiter pool & short-term investments) No material debt
Slide 23: Q2 FY25 Select Financial Metrics
Q2 FY25 Select Financial Metrics In $000s unless otherwise indicated KEY FINANCIAL METRICS Q2’25 Q2’24 % Change Gross revenue 102,763 57,425 79% Excise taxes (37,163) (19,797) 88% Net revenue 65,600 37,628 74% Cost of sales 45,813 26,366 74% Gross margin 18,418 9,600 92% Adjusted gross margin1 Ad
Slide 24: Q2 FY25 Select Balance Sheet Metrics
Q2 FY25 Select Balance Sheet Metrics In $000s unless otherwise indicated SELECT BALANCE SHEET METRICS Q2’25 Q4’24 % Change Cash & Restricted Cash 82,500 132,605 (38)% Short term investments 873 821 6% Biological assets & inventories 115,049 82,524 39% Prepaid expenses & deposits 10,093 9,
Slide 25: Capital Structure
Capital Structure In $000s unless otherwise indicated CAPITAL STRUCTURE 03-31-2025 05-07-2025 Common shares issued and outstanding 133,836 133,884 Preferred shares1 13,794 13,794 Options 2,622 2,595 Warrants 4,451 4,451 Top-up rights 17,534 17,499 Restricted share units 3,505 3,443 Performance